Download PDF
Semin Neurol 2024; 44(01): 053-063
DOI: 10.1055/s-0043-1777422
Review Article

Management of Neurologic Complications in Patients with Brain and Spine Tumors

Alipi V. Bonm
1   Department of Neurology, Swedish Neuroscience Institute, Seattle, Washington
,
Lynne P. Taylor
2   Department of Neurology, University of Washington, Seattle, Washington
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Patients with brain and spine tumors represent a distinct population with unique needs. We provide a practical review of neurologic care in this group with an emphasis on familiarizing the general neurologist to the nuances of neuro-oncologic supportive care. We review the management of cerebral edema, steroid dosing, and pertinent side effects. We discuss seizure management, including choice of anticonvulsants, putative antitumor effects, and important seizure mimics like drop attacks. We review the presentation and symptomatology of stroke-like migraine attack after radiation therapy (SMART syndrome). We describe the signs and symptoms that should prompt concern for metastatic spinal cord compression, as well as both acute and definitive treatment options. Finally, we discuss the underappreciated incidence of venous thromboembolic events, particularly in patients with gliomas, and review the data on management.

Keywords

steroids - seizures - headache - neurologic complications - cerebral edema


Publication History

Article published online:
04 January 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol 2014; 722: 48-54
    CrossrefPubMedGoogle Scholar
  • 2 Vecht CJ, Hovestadt A, Verbiest HBC, van Vliet JJ, van Putten WLJ. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44 (04) 675-680
    CrossrefPubMedGoogle Scholar
  • 3 Oki K, Yamane K. Therapies for adrenal insufficiency. Expert Opin Pharmacother 2007; 8 (09) 1283-1291
    CrossrefPubMedGoogle Scholar
  • 4 Okazaki SI, Yamakawa M, Maeda K, Ohta N, Aoyagi M. Expression of glucocorticoid receptors in non-neoplastic lymphoid follicles and B cell type malignant lymphomas. J Clin Pathol 2006; 59 (04) 410-416
    CrossrefPubMedGoogle Scholar
  • 5 Pirotte B, Levivier M, Goldman S, Brucher JM, Brotchi J, Hildebrand J. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. J Neurooncol 1997; 32 (01) 63-69
    CrossrefPubMedGoogle Scholar
  • 6 Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM. How we treat primary central nervous system lymphoma. ESMO Open 2021; 6 (04) 100213
    CrossrefPubMedGoogle Scholar
  • 7 Rubenstein J, Gupta N, Mannis G, LaMarre AK, Treseler P. How I treat CNS lymphomas. Blood 2013; 122 (14) 2318-2330
    CrossrefPubMedGoogle Scholar
  • 8 Wilkinson ID, Jellineck DA, Levy D. et al. Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging. Neurosurgery 2006; 58 (04) 640-646 , discussion 640–646
    CrossrefPubMedGoogle Scholar
  • 9 Narang VS, Fraga C, Kumar N. et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol 2008; 295 (02) C440-C450
    CrossrefPubMedGoogle Scholar
  • 10 Jessurun CAC, Hulsbergen AFC, de Wit AE. et al. The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. Neuro-oncol 2021; 23 (08) 1261-1272
    CrossrefPubMedGoogle Scholar
  • 11 Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, D'Antona G. Steroid myopathy: some unresolved issues. J Endocrinol Invest 2011; 34 (05) 370-375
    CrossrefPubMedGoogle Scholar
  • 12 Chen Y, Guo L, Li X, Liu R, Ren C, Du S. Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis. Clin Neurol Neurosurg 2020; 198: 106239
    CrossrefPubMedGoogle Scholar
  • 13 Levin VA, Mendelssohn ND, Chan J. et al. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neurooncol 2015; 122 (01) 145-150
    CrossrefPubMedGoogle Scholar
  • 14 Dewan MC, Thompson RC, Kalkanis SN, Barker II FG, Hadjipanayis CG. Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS/CNS Section on Tumors survey. J Neurosurg 2017; 126 (06) 1772-1778
    CrossrefPubMedGoogle Scholar
  • 15 Walbert T, Harrison RA, Schiff D. et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro-oncol 2021; 23 (11) 1835-1844
    CrossrefPubMedGoogle Scholar
  • 16 Chang SM, Messersmith H, Ahluwalia M. et al. Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: ASCO and SNO endorsement of the Congress of Neurological Surgeons Guidelines. J Clin Oncol 2019; 37 (13) 1130-1135
    CrossrefPubMedGoogle Scholar
  • 17 Chandra V, Rock AK, Opalak C. et al. A systematic review of perioperative seizure prophylaxis during brain tumor resection: the case for a multicenter randomized clinical trial. Neurosurg Focus 2017; 43 (05) E18
    CrossrefPubMedGoogle Scholar
  • 18 Greenhalgh J, Weston J, Dundar Y, Nevitt SJ, Marson AG. Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Cochrane Database Syst Rev 2020; 4 (04) CD007286
    PubMedGoogle Scholar
  • 19 van der Meer PB, Dirven L, Fiocco M. et al. First-line antiepileptic drug treatment in glioma patients with epilepsy: levetiracetam vs valproic acid. Epilepsia 2021; 62 (05) 1119-1129
    CrossrefPubMedGoogle Scholar
  • 20 Kerkhof M, Dielemans JCM, van Breemen MS. et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro-oncol 2013; 15 (07) 961-967
    CrossrefPubMedGoogle Scholar
  • 21 de Bruin ME, van der Meer PB, Dirven L, Taphoorn MJB, Koekkoek JAF. Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review. Neurooncol Pract 2021; 8 (05) 501-517
    PubMedGoogle Scholar
  • 22 Mo F, Meletti S, Belcastro V. et al. Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study. J Neurooncol 2022; 157 (03) 551-559
    CrossrefPubMedGoogle Scholar
  • 23 Rudà R, Pellerino A, Franchino F. et al. Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. J Neurooncol 2018; 136 (01) 105-114
    CrossrefPubMedGoogle Scholar
  • 24 Villanueva V, Saiz-Diaz R, Toledo M. et al. NEOPLASM study: real-life use of lacosamide in patients with brain tumor-related epilepsy. Epilepsy Behav 2016; 65: 25-32
    CrossrefPubMedGoogle Scholar
  • 25 van der Meer PB, Dirven L, Fiocco M. et al. Effectiveness of antiseizure medication duotherapies in patients with glioma: a multicenter observational cohort study. Neurology 2022; 99 (10) e999-e1008
    CrossrefPubMedGoogle Scholar
  • 26 Happold C, Gorlia T, Chinot O. et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 2016; 34 (07) 731-739
    CrossrefPubMedGoogle Scholar
  • 27 Venkatesh HS, Morishita W, Geraghty AC. et al. Electrical and synaptic integration of glioma into neural circuits. Nature 2019; 573 (7775) 539-545
    CrossrefPubMedGoogle Scholar
  • 28 Gillespie S, Monje M. An active role for neurons in glioma progression: making sense of Scherer's structures. Neuro-oncol 2018; 20 (10) 1292-1299
    CrossrefPubMedGoogle Scholar
  • 29 Grossman SA, Ye X, Chamberlain M. et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 2009; 27 (25) 4155-4161
    CrossrefPubMedGoogle Scholar
  • 30 Izumoto S, Miyauchi M, Tasaki T. et al. Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel. Anticancer Res 2018; 38 (07) 4361-4366
    CrossrefPubMedGoogle Scholar
  • 31 Motomura K, Chalise L, Shimizu H. et al. Intraoperative seizure outcome of levetiracetam combined with perampanel therapy in patients with glioma undergoing awake brain surgery. J Neurosurg 2021; 135 (04) 998-1007
    CrossrefPubMedGoogle Scholar
  • 32 Buckner J, Giannini C, Eckel-Passow J. et al. Management of diffuse low-grade gliomas in adults - use of molecular diagnostics. Nat Rev Neurol 2017; 13 (06) 340-351
    CrossrefPubMedGoogle Scholar
  • 33 Ranjan S, Schiff D. Acetazolamide for treatment of drop attacks due to symptomatic plateau waves: a case report. Neurology 2015. https://doi.org/10.1212/wnl.84.14_supplement.p4.211
    PubMedGoogle Scholar
  • 34 Singh TD, Hajeb M, Rabinstein AA. et al. SMART syndrome: retrospective review of a rare delayed complication of radiation. Eur J Neurol 2021; 28 (04) 1316-1323
    CrossrefPubMedGoogle Scholar
  • 35 Black DF, Morris JM, Lindell EP. et al. Stroke-like migraine attacks after radiation therapy (SMART) syndrome is not always completely reversible: a case series. AJNR Am J Neuroradiol 2013; 34 (12) 2298-2303
    CrossrefPubMedGoogle Scholar
  • 36 Winter SF, Klein JP, Vaios EJ. et al. Clinical presentation and management of SMART syndrome. Neurology 2021; 97 (03) 118-120
    CrossrefPubMedGoogle Scholar
  • 37 Heugenhauser J, Iglseder S, Muigg A. et al. Perampanel in brain tumor and SMART-syndrome related epilepsy - a single institutional experience. J Neurol Sci 2021; 423: 117386
    CrossrefPubMedGoogle Scholar
  • 38 Lawton AJ, Lee KA, Cheville AL. et al. Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol 2019; 37 (01) 61-71
    CrossrefPubMedGoogle Scholar
  • 39 Patchell RA. Metastatic epidural spinal cord compression. Eur J Cancer, Suppl 2007; 5 (05) 35-40
    CrossrefPubMedGoogle Scholar
  • 40 Fisher CG, DiPaola CP, Ryken TC. et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine 2010; 35 (22) E1221-E1229
    CrossrefPubMedGoogle Scholar
  • 41 Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002; 2002 (02) CD002068
    PubMedGoogle Scholar
  • 42 Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine 2005; 30 (19) 2186-2191
    CrossrefPubMedGoogle Scholar
  • 43 Leithner A, Radl R, Gruber G. et al. Predictive value of seven preoperative prognostic scoring systems for spinal metastases. Eur Spine J 2008; 17 (11) 1488-1495
    CrossrefPubMedGoogle Scholar
  • 44 Schoenfeld AJ, Le HV, Marjoua Y. et al. Assessing the utility of a clinical prediction score regarding 30-day morbidity and mortality following metastatic spinal surgery: the New England Spinal Metastasis Score (NESMS). Spine J 2016; 16 (04) 482-490
    CrossrefPubMedGoogle Scholar
  • 45 Patchell RA, Tibbs PA, Regine WF. et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366 (9486) 643-648
    CrossrefPubMedGoogle Scholar
  • 46 Rades D, Huttenlocher S, Dunst J. et al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol 2010; 28 (22) 3597-3604
    CrossrefPubMedGoogle Scholar
  • 47 Graham PH, Capp A, Delaney G. et al. A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. Clin Oncol (R Coll Radiol) 2006; 18 (01) 70-76
    CrossrefPubMedGoogle Scholar
  • 48 George R, Jeba J, Ramkumar G, Chacko AG, Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 2015; 2015 (09) CD006716
    PubMedGoogle Scholar
  • 49 Prewett S, Venkitaraman R. Metastatic spinal cord compression: review of the evidence for a radiotherapy dose fractionation schedule. Clin Oncol (R Coll Radiol) 2010; 22 (03) 222-230
    CrossrefPubMedGoogle Scholar
  • 50 Maranzano E, Trippa F, Casale M. et al. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol 2009; 93 (02) 174-179
    CrossrefPubMedGoogle Scholar
  • 51 Rades D, Cacicedo J, Conde-Moreno AJ. et al. Precision radiation therapy for metastatic spinal cord compression: final results of the PRE-MODE trial. Int J Radiat Oncol Biol Phys 2020; 106 (04) 780-789
    CrossrefPubMedGoogle Scholar
  • 52 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (04) 458-464
    CrossrefPubMedGoogle Scholar
  • 53 Diaz M, Jo J, Smolkin M, Ratcliffe SJ, Schiff D. Risk of venous thromboembolism in grade II-IV gliomas as a function of molecular subtype. Neurology 2021; 96 (07) e1063-e1069
    CrossrefPubMedGoogle Scholar
  • 54 Carrabba G, Riva M, Conte V. et al. Risk of post-operative venous thromboembolism in patients with meningioma. J Neurooncol 2018; 138 (02) 401-406
    CrossrefPubMedGoogle Scholar
  • 55 Cote DJ, Smith TR. Venous thromboembolism in brain tumor patients. J Clin Neurosci 2016; 25: 13-18
    CrossrefPubMedGoogle Scholar
  • 56 Perry SL, Bohlin C, Reardon DA. et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009; 95 (01) 129-134
    CrossrefPubMedGoogle Scholar
  • 57 Robins HI, O'Neill A, Gilbert M. et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 2008; 62 (02) 227-233
    CrossrefPubMedGoogle Scholar
  • 58 Perry JR, Julian JA, Laperriere NJ. et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8 (09) 1959-1965
    CrossrefPubMedGoogle Scholar
  • 59 Alvarado G, Noor R, Bassett R. et al. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 2012; 22 (04) 310-315
    CrossrefPubMedGoogle Scholar
  • 60 Donato J, Campigotto F, Uhlmann EJ. et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood 2015; 126 (04) 494-499
    CrossrefPubMedGoogle Scholar
  • 61 Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost 2016; 14 (09) 1736-1740
    CrossrefPubMedGoogle Scholar
  • 62 Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89 (03) 640-646
    CrossrefPubMedGoogle Scholar
  • 63 Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood 2017; 129 (25) 3379-3385
    CrossrefPubMedGoogle Scholar
  • 64 Lee AYY, Levine MN, Baker RI. et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 65 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedGoogle Scholar
  • 66 Carney BJ, Uhlmann EJ, Puligandla M. et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost 2019; 17 (01) 72-76
    CrossrefPubMedGoogle Scholar
  • 67 Reed-Guy L, Desai AS, Phillips RE. et al. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: a retrospective cohort study. Neuro-oncol 2022; 24 (12) 2172-2179
    CrossrefPubMedGoogle Scholar
  • 68 Dubinski D, Won SY, Voss M. et al. Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma. Neurosurg Rev 2022; 45 (01) 451-457
    CrossrefPubMedGoogle Scholar
  • 69 Norden AD, Bartolomeo J, Tanaka S. et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012; 106 (01) 121-125
    CrossrefPubMedGoogle Scholar
  • 70 Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol 2008; 7 (05) 459-466
    CrossrefPubMedGoogle Scholar